HOME >> MEDICINE >> NEWS
Access to antiretrovirals unlikely to reduce HIV infection rates

A new study by Rebecca Baggaley, Neil Ferguson, and Geoff Garnett (of Imperial College London) suggests that the HIV epidemic in poor countries will not be controlled through antiretroviral drugs alone, even if universal access is achieved. As they demonstrate in an article in the open-access international medical journal PLoS Medicine, without additional prevention methods such as counseling patients and their communities about safe sex, access to drugs is likely to increase HIV/AIDS prevalence.

Sexual transmission of HIV is more likely if the HIV-positive partner has a higher viral load. Because antiretrovirals therapy (ART) slows AIDS progression and reduces viral load in infected individuals, the drugs not only improve the health and prolong the life of those who take them, but also make it less likely that they infect others. As a consequence, ART has been discussed not only as a treatment but also as a prevention tool in its own right.

To test this, Baggaley and colleagues used a model to predict and compare the impacts of alternative strategies of increasing ART access in resource-poor countries. Some of the strategies included the provision of diagnostic laboratories that could routinely measure CD4 counts and viral loads of HIV-infected individuals (only if this is done could people be treated before they develop overt symptoms). They also took into account different ways that people might change their sexual behavior if they get treatment (which might make them feel physically better and more likely to be sexually active) and counseling (which will hopefully increase safe sex practices).

They found that providing ART to all individuals with AIDS symptoms (i.e. those at the late stages of the disease) was likely to increase the prevalence of HIV infection, as these people live longer and become sexually active again. If ART is also provided to HIV-positive individuals at an earlier stage, i.e. when their immune system starts to get
'"/>

Contact: Andrew Hyde
ahyde@plos.org
44-122-346-3330
Public Library of Science
13-Mar-2006


Page: 1 2

Related medicine news :

1. Access to alcohol among middle school children
2. Access to science enhanced by new NIH-ASH agreement
3. Access to existing medical treatments could save more lives than spending to improve the treatments
4. Accessible technology and rehab medicine help Americans with disabilities in todays work force
5. Access to mammography may worsen
6. Highly active antiretrovirals for HIV can substantially reduce rates of AIDS
7. Offenders unlikely to seek help when experiencing mental distress
8. Effects of new sleep medication appear unlikely to have potential for abuse or cognitive impairment
9. Search for cancer genes unlikely to succeed, say experts
10. Ozone recovering, but unlikely to stabilize at pre-1980 levels, says study
11. Nearly half of public health employees unlikely to work during pandemic

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Access antiretrovirals unlikely reduce HIV infection rates

(Date:10/22/2014)... October 22, 2014 For Dr. Iris Hunter, ... money; it’s an extension of her life’s mission. Her extensive ... as the owner of FirstLight HomeCare, make it clear that ... to me that my work makes a difference in the ... entrepreneurial spirit, so after much research, I felt ready to ...
(Date:10/22/2014)... The Louis W. Sullivan Institute ... distribute health information technology innovation to transform quality ... development of six key guiding principles of patient-centered ... These are an expansion of the Institute of ... is respectful of and responsive to individual patient ...
(Date:10/22/2014)... Best Cheap Hosting USA is among the most ... recently announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ) is the ... the world. , “iPower is one of the most ... various kinds of useful products for new and old ... customer service and a number of features which will ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Lintelus, Inc., ... Sr. Vice President of Sales, will be speaking on ... Meetings Technology Expo on October 28, at the Holiday ... hosting a booth as well as a Tech Demo ... Meeting can create a more engaging event experience. , ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 (HealthDay ... only about half as likely as white women to become ... and the racial disparity persists even when donor eggs are ... patients became pregnant after IVF, compared to about 17 percent ... over two years to tease out the impact of race, ...
Breaking Medicine News(10 mins):Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3
(Date:10/22/2014)... October 22, 2014 Oramed ... a clinical-stage pharmaceutical company focused on the development ... top-line clinical results from its Phase IIa clinical ... capsules, to treat type 1 diabetes. The trial was ... under a U.S. Food and Drug Administration ...
(Date:10/22/2014)... Colo. , Oct. 22, 2014   Surefire ... of infusion systems designed to maximize targeted delivery of ... pleased to announce that oncologist John R. Daniels ... Comprehensive Cancer Center, and surgical oncologist Steven C. ... have joined the Company,s Scientific Advisory Board (SAB).    ...
(Date:10/22/2014)... NEW YORK , Oct. 22, 2014 ... and dermatology therapies. PV-10, its novel investigational drug for ... the potential for systemic side effects. Its oncology focus ... liver. Provectus has completed phase 2 trials of PV-10 ... as a topical treatment for atopic dermatitis and psoriasis. ...
Breaking Medicine Technology:Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 4Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2
Cached News: